Mubadala Investment Company’s Bristol-Myers Squibb BMY Stock Holding History

Mubadala Investment Company’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Sell	212,761 -20,676	-9%	-$1.19M	0.04%	21
2026 Q1	$14.2M	Sell	233,437 -23,196	-9%	-$1.35M	0.07%	9
2025 Q4	$13.8M	Buy	256,633 +74,961	+41%	+$3.61M	0.08%	13
2025 Q3	$8.19M	Buy	181,672 +117,020	+181%	+$5.47M	0.05%	16
2025 Q2	$2.99M	Sell	64,652 -4,443	-6%	-$218K	0.02%	36
2025 Q1	$4.21M	Buy	+69,095	New	+$4.03M	0.02%	15

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mubadala Investment Company's BMY Position: Q2 2026 in Review

Mubadala Investment Company reduced its Bristol-Myers Squibb (BMY) stake by 8.9% in Q2 2026, selling an estimated $1.19M and leaving 212,761 shares worth $12.3M. The position accounts for 0.04% of the portfolio, ranked #21.

Mubadala Investment Company first reported a position in BMY in Q1 2025 and has held it in 6 quarters since. The position peaked at $14.2M in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Mubadala Investment Company held 212,761 shares of Bristol-Myers Squibb worth $12.3M as of Q2 2026.
Mubadala Investment Company sold 20,676 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.19M.
Bristol-Myers Squibb made up 0.04% of Mubadala Investment Company's portfolio in Q2 2026, its #21 holding.
Mubadala Investment Company first reported a position in Bristol-Myers Squibb in Q1 2025 and has held it in 6 quarters since.
Mubadala Investment Company's Bristol-Myers Squibb position peaked at $14.2M in Q1 2026.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Mubadala Investment Company's 13F filing for Q2 2026, filed 14 Aug 2026.